

## DAFTAR PUSTAKA

- Abbas, A. (2017). Monitoring Efek Samping Obat Anti-Tuberkulosis (OAT) Pada Pengobatan Tahap Intensif Penderita TB Paru Di Kota Makassar. *Journal of Agromedicine and Medical Sciences*, 3(1).
- Abdulkadir, W., Djuwarno, E. N., Rasdiana, N., & Hiola, F. (2023). Gambaran Efek Samping Obat Antituberkulosis Pada Pasien Tuberkulosis. *Journal Syifa Sciences and Clinical Research*, 4(1).
- Abulfathi, A. A., Decloedt, E. H., Svensson, E. M., Diacon, A. H., Donald, P., & Reuter, H. (2019). Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. In *Clinical Pharmacokinetics* (Vol. 58, Issue 9). <https://doi.org/10.1007/s40262-019-00764-2>
- Alffenaar, J. W. C., Stocker, S. L., Forsman, L. D., Garcia-Prats, A., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Oñata, W. A., Bhavani, P. K., van't Bovenind-Vrubleuskaya, N., Carvalho, A. C. C., Centis, R., Chakaya, J. M., Cirillo, D. M., Cho, J. G., D'Ambrosio, L., Dalcolmo, M. P., ... Migliori, G. B. (2022). Clinical standards for the dosing and management of TB drugs. *International Journal of Tuberculosis and Lung Disease*, 26(6). <https://doi.org/10.5588/ijtld.22.0188>
- Alsayed, S. S. R., & Gunosewoyo, H. (2023). Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. In *International Journal of Molecular Sciences* (Vol. 24, Issue 6). <https://doi.org/10.3390/ijms24065202>
- Al-Shaer, M. H., Mansour, H., Elewa, H., Salameh, P., & Iqbal, F. (2017). Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. *BMC Infectious Diseases*, 17(1). <https://doi.org/10.1186/s12879-017-2231-1>
- Badan Pusat Statistik Indonesia. (2024). Statistik Indonesia 2024. In *Statistik Indonesia 2020* (Vol. 1101001).
- Berhan, A., Almaw, A., Solomon, Y., Legese, B., Damtie, S., Erkihun, M., Alebachew, Z., Eyayu, T., & Getie, G. A. B. (2023). Tuberculosis Treatment Outcome and Associated Factors Among Tuberculosis Patients Linked to Tuberculosis Treatment Clinics in Ethiopia, 2023: A Multi-Center Retrospective Study. *Infection and Drug Resistance*, 16. <https://doi.org/10.2147/IDR.S413272>
- BPOM RI. (2020). Modul Farmakovigilans Untuk Tenaga Profesional Kesehatan Proyek "Ensuring Drug and Food Safety." In *Badan Pengawas Obat dan Makanan (BPOM) RI*.
- BPS Jabar. (2024). Provinsi Jawa Barat dalam Angka 2024. In *Provinsi Jawa Barat dalam Angka* (Vol. 49, Issue 1).
- Brenner, G. M., & Stevens, C. W. (2018). Brennerand Stevens' PHARMACOLOGY. In *Elsevier*.

- Brunton, L., Parker, K., Blumenthal, D., & Buxton, I. (2008). Goodman & Gilman's: Manual of Pharmacology and Therapeutics. In *Pharmacology & Therapeutics* (Vol. 95).
- Chung, S. J., Byeon, S. J., & Choi, J. H. (2022). Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System. *Journal of Korean Medical Science*, 37(16). <https://doi.org/10.3346/jkms.2022.37.e128>
- de Vries, S. T., Denig, P., Ekhart, C., Burgers, J. S., Kleefstra, N., Mol, P. G. M., & van Puijenbroek, E. P. (2019). Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. *British Journal of Clinical Pharmacology*, 85(7). <https://doi.org/10.1111/bcp.13923>
- Dirjen P2P. (2023). Laporan Program Penanggulangan Tuberkulosis Tahun 2022. In *Kemenkes RI*.
- Djochie, R. D. A., Anto, B. P., & Opare-Addo, M. N. A. (2023). Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study. *Journal of Pharmaceutical Policy and Practice*, 16(1). <https://doi.org/10.1186/s40545-023-00577-6>
- DOH. (2014). *Manual of Procedures of the National Tuberculosis Control Program 5th Edition*. [www.doh.gov.ph/sites/default/files/%0Antp\\_2001.html](http://www.doh.gov.ph/sites/default/files/%0Antp_2001.html) and at [itis.doh.gov.ph/mop\\_2014.pdf](http://itis.doh.gov.ph/mop_2014.pdf)
- Due, A. (2023). What are side effects? *European Journal for Philosophy of Science*, 13(1). <https://doi.org/10.1007/s13194-023-00519-8>
- El-Kholy, M. M., Sadek, S. H., & Mahran, O. (2018). Fixed-dose combination versus separate drug formula for pulmonary and extrapulmonary tuberculosis. *Egyptian Journal of Bronchology*, 12(3). [https://doi.org/10.4103/ejb.ejb\\_61\\_17](https://doi.org/10.4103/ejb.ejb_61_17)
- Fei, C. M., Zainal, H., & Hyder Ali, I. A. (2018). Evaluation of adverse reactions induced by anti-tuberculosis drugs in hospital Pulau Pinang. *Malaysian Journal of Medical Sciences*, 25(5). <https://doi.org/10.21315/mjms2018.25.5.10>
- Gary C. Rosenfeld, PhD, David S. Loose, P. (2015). BRS Pharmacology 6th. In *Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis* (Vol. 53, Issue 9).
- Hussain, Z., Zhu, J., & Ma, X. (2021). Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. In *Drug Metabolism and Disposition* (Vol. 49, Issue 8). <https://doi.org/10.1124/DMD.121.000389>
- Imam, F., Sharma, M., Khayyam, K. U., Al-Harbi, N. O., Rashid, M. K., Ali, M. D., Ahmad, A., & Qamar, W. (2020). Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs. *Saudi Pharmaceutical Journal*, 28(3). <https://doi.org/10.1016/j.jsps.2020.01.011>

- Indonesia, M. K. R. (2019). Pedoman nasional pelayanan kedokteran tata laksana tuberkulosis. *Kementerian Kesehatan*, 224(11).
- Johnston, J. C., Cooper, R., & Menzies, D. (2022). Chapter 5: Treatment of tuberculosis disease. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, 6(S1). <https://doi.org/10.1080/24745332.2022.2036504>
- Katzung, B. G. (2018). *Katzung Basic & Clinical Pharmacology 12th Ed2*. In *McGraw-Hill Education*.
- Kaufman, G. (2016). Adverse drug reactions: classification, susceptibility and reporting. *Nursing Standard (Royal College of Nursing (Great Britain) : 1987)*, 30(50). <https://doi.org/10.7748/ns.2016.e10214>
- Kemnterian Kesehatan RI, 2018. (2018). Laporan Nasional Riskesdas Tahun 2018. In *Lembaga Penerbit Balitbangkes*.
- Kwon, B. S., Kim, Y., Lee, S. H., Lim, S. Y., Lee, Y. J., Park, J. S., Cho, Y. J., Yoon, H. Il, Lee, C. T., & Lee, J. H. (2020). The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. *PLoS ONE*, 15(7 July). <https://doi.org/10.1371/journal.pone.0236109>
- Lei, S., Gu, R., & Ma, X. (2021). Clinical perspectives of isoniazid-induced liver injury. In *Liver Research* (Vol. 5, Issue 2). <https://doi.org/10.1016/j.livres.2021.02.001>
- Li, Y., Zhao, L., Hou, M., Gao, T., Sun, J., Luo, H., Wang, F., Zhong, F., Ma, A., & Cai, J. (2022). Lactobacillus casei Improve Anti-Tuberculosis Drugs-Induced Intestinal Adverse Reactions in Rat by Modulating Gut Microbiota and Short-Chain Fatty Acids. *Nutrients*, 14(8). <https://doi.org/10.3390/nu14081668>
- Luies, L., & Preez, I. du. (2020). The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications. In *Clinical Microbiology Reviews* (Vol. 33, Issue 4). <https://doi.org/10.1128/CMR.00036-20>
- Maharani, M. W., Yusmaini, H., Karina, K., & ... (2024). Hubungan Pemberian Obat Anti Tuberkulosis dengan Kejadian Efek Sampingnya pada Pasien Tuberkulosis Paru Di RSUD Sumedang Tahun 2022. *Seminar Nasional ...*, 35–42. <https://conference.upnvj.ac.id/index.php/sensorik/article/view/2800%0Ahttps://conference.upnvj.ac.id/index.php/sensorik/article/download/2800/1988>
- Maiti, S., Parua, S., Nandi, D. K., Mondal, K. C., & Samanta, S. (2019). Hepatotoxic effect of Rifampicin as an Anti-Tuberculosis drug on male Albino rat. *Journal of Drug Delivery and Therapeutics*, 9(3). <https://doi.org/10.22270/jddt.v9i3.2744>
- Maulitha, F., Fitriani, N., & Rusli, R. (2022). Analisis Efek Samping Penggunaan Obat Antituberkulosis (OAT) di Instalasi Rawat Jalan RSD BLUD dr. H. Soemarno Sosroatmodjo Tanjung Selor. *Proceeding of Mulawarman Pharmaceuticals Conferences*, 16. <https://doi.org/10.25026/mpc.v16i1.656>

- Meyrisca, M., Susanti, R., & Nurmainah. (2022). Hubungan Kepatuhan Penggunaan Obat Anti Tuberkulosis Dengan Keberhasilan Pengobatan Pasien Tuberkulosis Di Puskesmas Sungai Betung Bengkayang. *Lambung Farmasi; Jurnal Ilmu Kefarmasian*, 3(2).
- Micaglio, E., Locati, E. T., Monasky, M. M., Romani, F., Heilbron, F., & Pappone, C. (2021). Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine. In *Frontiers in Pharmacology* (Vol. 12). <https://doi.org/10.3389/fphar.2021.651720>
- MISHRA, G., MUNJE, R., & MATE, K. (2022). ANTI-TB TREATMENT-INDUCED ARTHRALGIA: AN OVERLOOKED AGONY OF THE PATIENT WITH TB. *Chest*, 161(6). <https://doi.org/10.1016/j.chest.2021.12.428>
- Molla, Y., Wubetu, M., & Dessie, B. (2021). Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia. *Hepatic Medicine: Evidence and Research, Volume 13*. <https://doi.org/10.2147/hmer.s290542>
- Ngo, M. D., Bartlett, S., & Ronacher, K. (2021). Diabetes-associated susceptibility to tuberculosis: Contribution of hyperglycemia vs. dyslipidemia. In *Microorganisms* (Vol. 9, Issue 11). <https://doi.org/10.3390/microorganisms9112282>
- Ningsih, A. S. W., Ramadhan, A. M., & Rahmawati, D. (2022). Kajian Literatur Pengobatan Tuberkulosis Paru dan Efek Samping Obat Antituberkulosis di Indonesia. *Proceeding of Mulawarman Pharmaceuticals Conferences*, 15. <https://doi.org/10.25026/mpc.v15i1.647>
- Nugroho, N. P., & Kusmiati, T. (2021). Allergic Reaction due to Anti-Tuberculosis Drugs, How to Manage? *Jurnal Respirasi*, 7(2). <https://doi.org/10.20473/jr.v7-i.2.2021.79-85>
- Peng, Y., Zhu, Q., Wang, B., & Ren, J. (2020). A cross-sectional study on interference control: Age affects reactive control but not proactive control. *PeerJ*, 2020(1). <https://doi.org/10.7717/peerj.8365>
- Perhimpunan Dokter Paru Indonesia. (2021). Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. In *Perhimpunan Dokter Paru Indonesia* (Vol. 001, Issue 2014).
- Prasad, R., Singh, A., & Gupta, N. (2019). Adverse drug reactions in tuberculosis and management. In *Indian Journal of Tuberculosis* (Vol. 66, Issue 4). <https://doi.org/10.1016/j.ijtb.2019.11.005>
- Rasdianah, N., Madania, Tuloli, T. S., Abdulkadir, W. S., Ahmad, H., & Suwandi, T. B. A. (2022). Studi Efek Samping Obat Antituberkulosis ( OAT ) Pada Pasien TB Paru. *Journal Syifa Sciences and Clinical Research (JSSCR)*, 4(3).

- Rocha, D. M. G. C., Viveiros, M., Saraiva, M., & Osório, N. S. (2021). The neglected contribution of streptomycin to the tuberculosis drug resistance problem. In *Genes* (Vol. 12, Issue 12). <https://doi.org/10.3390/genes12122003>
- Sandu Siyoto dan Ali Sodik. (2015). Dasar Metodologi Penelitian. *Literasi Media Publishing*.
- Sankar, J., Chauhan, A., Singh, R., & Mahajan, D. (2024). Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. *Frontiers in Pharmacology*, 15(September), 1–20. <https://doi.org/10.3389/fphar.2024.1441147>
- Sant'Anna, F. M., Araújo-Pereira, M., Schmaltz, C. A. S., Arriaga, M. B., de Oliveira, R. V. C., Andrade, B. B., & Rolla, V. C. (2021). Adverse Drug Reactions Related to Treatment of Drug-Susceptible Tuberculosis in Brazil: A Prospective Cohort Study. *Frontiers in Tropical Diseases*, 2. <https://doi.org/10.3389/fitd.2021.748310>
- Sant-Anna, F. M., Araújo-Pereira, M., Schmaltz, C. A. S., Arriaga, M. B., Andrade, B. B., & Rolla, V. C. (2023). Impact of adverse drug reactions on the outcomes of tuberculosis treatment. *PLoS ONE*, 18(2 February). <https://doi.org/10.1371/journal.pone.0269765>
- Shah, S., Adhikari, Y. R., Paudel, S., Sitaula, S., Koirala, B., Aryal, S., Pande, Y., & Karki, R. (2022). Optic neuropathy induced by ethambutol: A rare case from Nepal. *Annals of Medicine and Surgery*, 77. <https://doi.org/10.1016/j.amsu.2022.103637>
- Sharma, R. K., Verma, G. K., Tegta, G. R., Sood, S., Rattan, R., & Gupta, M. (2020). Spectrum of Cutaneous Adverse Drug Reactions to Anti-tubercular Drugs and Safe Therapy after Re-challenge - A Retrospective Study. *Indian Dermatology Online Journal*, 11(2). [https://doi.org/10.4103/idoj.IDOJ\\_133\\_19](https://doi.org/10.4103/idoj.IDOJ_133_19)
- Sileshi, T., Telele, N. F., Burkley, V., Makonnen, E., & Aklillu, E. (2023). Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients. *Scientific Reports*, 13(1). <https://doi.org/10.1038/s41598-023-38716-3>
- Silva, D. R., Muñoz-Torrico, M., Duarte, R., Galvão, T., Bonini, E. H., Arbex, F. F., Arbex, M. A., Augusto, V. M., Rabahi, M. F., & Mello, F. C. de Q. (2018). Risk factors for tuberculosis: Diabetes, smoking, alcohol use, and the use of other drugs. In *Jornal Brasileiro de Pneumologia* (Vol. 44, Issue 2). <https://doi.org/10.1590/s1806-37562017000000443>
- Sitepu, R., Ascobat, P., Ekasari, F., & Instiaty, I. (2018). Fixed-dose combination versus separate antituberculosis formulations in pulmonary tuberculosis patients: Evaluation of effectiveness and safety. *International Journal of Applied Pharmaceutics*, 10(Special Issue 1). <https://doi.org/10.22159/ijap.2018.v10s1.46>

- Syarif, A., Estuningtyas, A., & Setiawati, A. (2012). Farmakologi dan Terapi FK UI Ed 5 (Cetak Ulang dengan Tambahan, 2012). In *Journal of Chemical Information and Modeling* (Vol. 53, Issue 9).
- Thontham, A., & Polsook, R. (2021). Symptom experience of adverse drug reaction among male and female patients with newly diagnosed pulmonary tuberculosis in Thailand. In *Belitung Nursing Journal* (Vol. 7, Issue 3). <https://doi.org/10.33546/bnj.1337>
- Wang, P., Pradhan, K., Zhong, X. bo, & Ma, X. (2016). Isoniazid metabolism and hepatotoxicity. In *Acta Pharmaceutica Sinica B* (Vol. 6, Issue 5). <https://doi.org/10.1016/j.apsb.2016.07.014>
- WHO. (2023). Global Report TB 2023. In *January: Vol. t/TB/* (Issue March).
- Wikurendra, E. A., Nurika, G., Tarigan, Y. G., & Kurnianto, A. A. (2021). Risk factors of pulmonary tuberculosis and countermeasures: A literature review. *Open Access Macedonian Journal of Medical Sciences*, 9. <https://doi.org/10.3889/oamjms.2021.7287>
- World Health Organization, W. (2022). GLOBAL TUBERCULOSIS REPORT:2022. GENEVA. In *World Health Organization 2022* (Vol. 375, Issue 9731).
- World Health Organization, (WHO). (2022). WHO consolidated guidelines on tuberculosis. In *WHO Press*.
- Wu, J. T., Chiu, C. T., Wei, Y. F., & Lai, Y. F. (2015). Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. *Clinics*, 70(6). [https://doi.org/10.6061/clinics/2015\(06\)08](https://doi.org/10.6061/clinics/2015(06)08)
- Zazzara, M. B., Palmer, K., Vetrano, D. L., Carfi, A., & Graziano, O. (2021). Adverse drug reactions in older adults: a narrative review of the literature. In *European Geriatric Medicine* (Vol. 12, Issue 3). <https://doi.org/10.1007/s41999-021-00481-9>
- Zhang, T., Du, J., Yin, X., Xue, F., Liu, Y., Li, R., Luo, C., Li, L., & Li, X. (2015). Adverse events in treating smear-positive tuberculosis patients in China. *International Journal of Environmental Research and Public Health*, 13(1). <https://doi.org/10.3390/ijerph13010086>
- Zucker, I., & Prendergast, B. J. (2020). Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biology of Sex Differences*, 11(1). <https://doi.org/10.1186/s13293-020-00308-5>
- Zuur, M. A., Akkerman, O. W., Forsman, L. D., Hu, Y., Zheng, R., Bruchfeld, J., Tiberi, S., Migliori, G. B., & Alffenaar, J. W. C. (2016). Fixed-dose combination and therapeutic drug monitoring in tuberculosis: Friend or foe? In *European Respiratory Journal* (Vol. 48, Issue 4). <https://doi.org/10.1183/13993003.00833-2016>